Survival and disease progression in UK patients with lymphangioleiomyomatosis.
about
Efficacy and safety of sirolimus in lymphangioleiomyomatosis."Getting stuck with LAM": patients perspectives on living with lymphangioleiomyomatosis.Diffuse Cystic Lung Disease. Part I.The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.Involvement of lymphatics in lymphangioleiomyomatosisUse of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis.A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM).Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosisPredictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis.Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosisLymphatic involvement in lymphangioleiomyomatosisLymphangioleiomyomatosis - a wolf in sheep's clothing.Prevalence and Predictive Value of Dyspnea Ratings in Hospitalized Patients: Pilot StudiesSt. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosisLymphangioleiomyomatosis and tuberous sclerosis complex.Multiple pneumothoraces during second and third trimesters as first presentation of lymphangioleiomyomatosis.A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.Renal angiomyolipoma and lymphangioleiomyomatosis in pregnancy.Familial syndromes associated with intracranial tumours: a review.The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management.Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry.Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre.Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective.[Chylothorax in an 87-year-old patient].Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function.Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge.Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.Clinical features of 280 hospitalized patients with lymphangioleiomyomatosis in Japan.Diagnosis of lymphangioleiomyomatosis in a 75-year-old woman.Computed tomography lymphangiography findings in 27 cases of lymphangioleiomyomatosis.Immunohistological features related to functional impairment in lymphangioleiomyomatosis.The epidemiology of lymphangioleiomyomatosis in Japan: A nationwide cross-sectional study of presenting features and prognostic factorsThe vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis
P2860
Q24610039-ACE3D663-AA84-4649-9925-6AF145BB6118Q33685049-341730E9-8E2B-479D-899E-9C6E1257B225Q33722950-A115AFED-A12C-4641-A7F3-5BCB01B70C11Q33905090-B7107252-5DD5-413C-BB41-A46973CEDBDEQ33905141-B4175FAE-D4F5-4F4F-A168-C0AE5BE322E5Q33963293-F7600E0D-B28E-4ED1-8E49-596EF535912FQ34061748-C364E9BE-F8DF-4977-BDC1-2FB8482B1E63Q34194187-5032DE57-D6F4-4906-9CE6-0C7E5379ECB7Q34536450-1443D9F0-C3F7-4777-8451-127163FAEE99Q34560457-BBAFB5A1-7310-4B64-B072-1CA404BD6FCAQ35531599-BF85FAAD-F120-486D-A389-980B0BE72893Q35610828-064507C7-DC76-451E-9F13-E8BD9B82F695Q36083291-FAA09DB0-5268-4B00-8172-48D022AB5DF2Q36357766-84E83EF9-EFE3-417E-B3EC-FEA906836E2EQ36791250-375F839D-8A3B-4122-B5A5-A0E85BE33B58Q36905344-1924BF93-91A8-49CC-8305-8BDADE121122Q37137669-15F4DF3E-3617-475B-9BE7-888AE9F1FEB7Q37186286-022EDC30-2A09-4826-B7F8-3C8EFF86D23AQ37937344-DCA67DD8-B30C-4536-AA50-7B8F173F0520Q38126965-84F4AB4B-32A7-440C-AE4F-317B2E1D8DC3Q38160164-D3D63B84-13BF-44F0-8FAF-614CCCE26BABQ38372196-F8F48DE9-D956-47C6-9E26-52C2907FC33EQ38414596-50BCC6C9-0558-429D-A25A-02748A5F290FQ38463698-7512F623-AD04-4F2A-B95C-E3BD75D9148AQ38617379-106061DD-7864-4421-BF41-58DF00633F6DQ46493091-74FE5BDD-9789-46D5-ABD0-E21DA0453996Q46850772-8E954E9A-FBE4-406A-BCA9-3CFE77D9EF4AQ47370738-B4B78155-0E47-4161-9617-7ADEAC822141Q47656318-C062C1A6-CF1C-463A-8092-759D8D7CB305Q48355779-F1BD2A3B-3DD6-48AB-A284-0EB99C91435AQ51684882-8FB117B7-D7FC-4C10-B71B-4DC558B5B9EAQ51709527-8256ADB4-AF36-4349-BDA3-29457BC60385Q52953570-1CB6B32E-9256-4BC6-B008-679DC47C3CB1Q54979000-7377932B-9C97-4509-9089-3545F273B33FQ55981832-35D63CC5-85E9-4C84-922D-F74A9402E5BBQ58701361-FD4E1D8A-897D-412E-A83A-2CFE4C220C56
P2860
Survival and disease progression in UK patients with lymphangioleiomyomatosis.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Survival and disease progression in UK patients with lymphangioleiomyomatosis.
@ast
Survival and disease progression in UK patients with lymphangioleiomyomatosis.
@en
Survival and disease progression in UK patients with lymphangioleiomyomatosis.
@nl
type
label
Survival and disease progression in UK patients with lymphangioleiomyomatosis.
@ast
Survival and disease progression in UK patients with lymphangioleiomyomatosis.
@en
Survival and disease progression in UK patients with lymphangioleiomyomatosis.
@nl
prefLabel
Survival and disease progression in UK patients with lymphangioleiomyomatosis.
@ast
Survival and disease progression in UK patients with lymphangioleiomyomatosis.
@en
Survival and disease progression in UK patients with lymphangioleiomyomatosis.
@nl
P2093
P2860
P356
P1433
P1476
Survival and disease progression in UK patients with lymphangioleiomyomatosis
@en
P2093
A E Tattersfield
R B Hubbard
P2860
P304
P356
10.1136/THX.2004.023283
P407
P577
2004-09-01T00:00:00Z